Foghorn Therapeutics Inc. (FHTX) Reports Q3 Loss, Beats Revenue Estimates

Group 1: Earnings Performance - Foghorn Therapeutics Inc. reported a quarterly loss of $0.25 per share, better than the Zacks Consensus Estimate of a loss of $0.31, representing an earnings surprise of +19.35% [1] - The company posted revenues of $8.15 million for the quarter ended September 2025, surpassing the Zacks Consensus Estimate by 1.12% and showing an increase from $7.81 million year-over-year [2] - Over the last four quarters, the company has surpassed consensus EPS estimates two times and topped consensus revenue estimates once [2] Group 2: Stock Performance and Outlook - Foghorn Therapeutics shares have declined approximately 25.2% since the beginning of the year, contrasting with the S&P 500's gain of 15.1% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.28 on revenues of $9.7 million, and for the current fiscal year, it is -$1.18 on revenues of $31.3 million [7] - The estimate revisions trend for Foghorn Therapeutics was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Group 3: Industry Context - The Medical - Biomedical and Genetics industry, to which Foghorn Therapeutics belongs, is currently in the top 40% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]